64 results on '"Ghanima, Waleed"'
Search Results
2. Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy
3. Physical activity following pulmonary embolism and clinical correlates in selected patients: a cross-sectional study
4. Incidence of venous thromboembolism, recurrence, and bleeding after isolated superficial vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital
5. Incidence of bleeding and recurrence in isolated distal deep vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital
6. The Effects of Exercise Training in Patients With Persistent Dyspnea Following Pulmonary Embolism: A Randomized Controlled Trial
7. A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial
8. Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry
9. SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people
10. The venous thrombosis registry in Østfold Hospital (TROLL registry) ‐ design and cohort description
11. Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
12. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow‐up
13. Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients
14. Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
15. Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
16. Health‐related quality‐of‐life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology
17. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns
18. Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
19. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study
20. Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis
21. Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
22. Gastric sleeve resection as day-case surgery: what affects the discharge time?
23. Updated international consensus report on the investigation and management of primary immune thrombocytopenia
24. Pain and nausea after bariatric surgery with total intravenous anesthesia versus desflurane anesthesia: a double blind, randomized, controlled trial
25. Cardiovascular and bleeding outcomes in a population‐based cohort of patients with chronic immune thrombocytopenia
26. Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study
27. “Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients ‐ 30 months follow‐up”: Reply
28. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
29. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities
30. Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility
31. An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination
32. A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)
33. Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag
34. The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0
35. Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia
36. Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders
37. Health Related Quality of Life in Patients with Primary ITP Compared with Population Norms: A Multicenter Retrospective Analysis of Data from Norwegian ITP Registry
38. Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)
39. Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry
40. Avatrombopag Plus Fostamatinib Combination Efficacy and Safety in Patients with Immune Thrombocytopenia
41. Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker
42. Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia
43. Fatigue after initiating rivaroxaban for venous thromboembolism
44. Bleedings in Cancer Patients Treated with Apixaban for Venous Thromboembolism
45. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
46. Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up
47. Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
48. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH
49. ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients
50. A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.